Giverny Capital Inc. Boosts Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Giverny Capital Inc. lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 234,287 shares of the company’s stock after acquiring an additional 7,215 shares during the quarter. Medpace accounts for about 2.8% of Giverny Capital Inc.’s holdings, making the stock its 13th biggest holding. Giverny Capital Inc. owned approximately 0.75% of Medpace worth $77,837,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Lindbrook Capital LLC increased its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the period. HBK Sorce Advisory LLC grew its holdings in shares of Medpace by 0.5% in the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock worth $1,789,000 after purchasing an additional 29 shares during the last quarter. Assetmark Inc. increased its stake in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after buying an additional 29 shares during the period. Proficio Capital Partners LLC raised its holdings in Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after buying an additional 29 shares during the last quarter. Finally, Schulhoff & Co. Inc. boosted its position in Medpace by 1.2% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock valued at $874,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on MEDP shares. Truist Financial decreased their price objective on shares of Medpace from $347.00 to $333.00 and set a “hold” rating on the stock in a research report on Thursday. Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target on the stock. Robert W. Baird increased their price objective on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Mizuho reduced their target price on Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a research note on Monday, March 24th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $361.90.

Medpace Trading Up 5.5 %

MEDP opened at $297.72 on Friday. The company has a market cap of $9.00 billion, a price-to-earnings ratio of 23.57, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. The stock has a fifty day simple moving average of $323.58 and a two-hundred day simple moving average of $334.41. Medpace Holdings, Inc. has a 12-month low of $272.00 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.